Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Preferred Stock Liabilities (2020 - 2023)

Mimedx's Preferred Stock Liabilities history spans 4 years, with the latest figure at $92.5 million for Q3 2023.

  • On a quarterly basis, Preferred Stock Liabilities changed 0.0% to $92.5 million in Q3 2023 year-over-year; TTM through Sep 2023 was $92.5 million, a 0.0% change, with the full-year FY2022 number at $92.5 million, changed 0.0% from a year prior.
  • Preferred Stock Liabilities hit $92.5 million in Q3 2023 for Mimedx, roughly flat from $92.5 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for MDXG hit a ceiling of $92.5 million in Q2 2021 and a floor of $91.1 million in Q3 2020.
  • Historically, Preferred Stock Liabilities has averaged $92.3 million across 4 years, with a median of $92.5 million in 2021.
  • Biggest five-year swings in Preferred Stock Liabilities: increased 1.52% in 2021 and later changed 0.0% in 2022.
  • Tracing MDXG's Preferred Stock Liabilities over 4 years: stood at $91.6 million in 2020, then grew by 1.01% to $92.5 million in 2021, then changed by 0.0% to $92.5 million in 2022, then changed by 0.0% to $92.5 million in 2023.
  • Business Quant data shows Preferred Stock Liabilities for MDXG at $92.5 million in Q3 2023, $92.5 million in Q2 2023, and $92.5 million in Q1 2023.